Adjuvant Therapy for NSCLC
This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Explain current recommendations for selecting adjuvant versus neoadjuvant therapy for patients with stage II and III non-small cell lung cancer
Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
- 0.75 Participation
- 0.76 Nurse
- 0.75 Pharmacist
- 0.75 Physician